Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danish non-inferiority study of ocrelizumab and rituximab in MS
2024-514287-84-00Phase 3Authorised
- Sponsor
- Rigshospitalet
- Start
- Aug 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple sclerosis (MS) comparing Ocrevus arm with Rituximab arm (2 arms). Planned start Aug 2024; status: authorised.
02
Drugs
ocrelizumabrituximab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-514287-84-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514287-84-00.